MX2020004155A - Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales. - Google Patents

Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.

Info

Publication number
MX2020004155A
MX2020004155A MX2020004155A MX2020004155A MX2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A
Authority
MX
Mexico
Prior art keywords
animals
treatment
diseases
prevention
fused heteroaromatic
Prior art date
Application number
MX2020004155A
Other languages
English (en)
Inventor
Ulf Bömer
Nils Griebenow
Gerald Beddies
Iring Heisler
Maria De Lourdes Mottier
Jörg Cramer
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2020004155A publication Critical patent/MX2020004155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente solicitud se refiere al uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y/o la profilaxis de enfermedades alérgicas y/o inflamatorias en los animales y se refiere a su uso para la producción de medicamentos para el tratamiento y/o profilaxis de enfermedades alérgicas y/o inflamatorias en los animales, especialmente de la dermatitis atópica y/o de la dermatitis alérgica por picadura de pulga, y especialmente en animales domésticos, particularmente en los perros.
MX2020004155A 2017-10-19 2018-10-15 Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales. MX2020004155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197344 2017-10-19
PCT/EP2018/078086 WO2019076817A1 (en) 2017-10-19 2018-10-15 USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS

Publications (1)

Publication Number Publication Date
MX2020004155A true MX2020004155A (es) 2020-08-03

Family

ID=60143623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004155A MX2020004155A (es) 2017-10-19 2018-10-15 Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.

Country Status (18)

Country Link
US (1) US11077111B2 (es)
EP (1) EP3665171A1 (es)
JP (1) JP2020537678A (es)
KR (1) KR20200073216A (es)
CN (1) CN111194319A (es)
AU (1) AU2018350683A1 (es)
BR (1) BR112020007679A2 (es)
CA (1) CA3079292A1 (es)
CL (1) CL2020001036A1 (es)
DO (1) DOP2020000093A (es)
IL (1) IL273834A (es)
MX (1) MX2020004155A (es)
PH (1) PH12020550444A1 (es)
RU (1) RU2020116178A (es)
SG (1) SG11202002475TA (es)
TW (1) TW201922744A (es)
UY (1) UY37945A (es)
WO (1) WO2019076817A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017898T2 (de) 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2523126A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ575410A (en) 2006-09-07 2012-03-30 Biogen Idec Inc 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives
KR20150043565A (ko) 2007-03-12 2015-04-22 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
RS55055B1 (sr) 2008-12-08 2016-12-30 Gilead Connecticut Inc Imidazopirazin syk inhibitori
CN102858767B (zh) 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
UA107100C2 (xx) 2009-12-23 2014-11-25 Конденсовані гетероароматичні піролідинони як інгібітори syk
LT2655357T (lt) 2010-12-20 2016-10-10 Merck Serono S.A. Indazolilo triazolo dariniai, kaip irak inhibitoriai
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
EP3110820B1 (en) * 2014-02-28 2022-04-06 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
UA120632C2 (uk) 2014-12-18 2020-01-10 Такеда Фармасьютікал Компані Лімітед Тверді форми конденсованих гетероароматичних піролідинонів
ES2930585T3 (es) * 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
SG11201809470RA (en) 2016-06-01 2018-11-29 Bayer Animal Health Gmbh Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

Also Published As

Publication number Publication date
DOP2020000093A (es) 2020-09-30
JP2020537678A (ja) 2020-12-24
IL273834A (en) 2020-05-31
SG11202002475TA (en) 2020-04-29
RU2020116178A (ru) 2021-11-19
EP3665171A1 (en) 2020-06-17
US11077111B2 (en) 2021-08-03
CA3079292A1 (en) 2019-04-25
TW201922744A (zh) 2019-06-16
PH12020550444A1 (en) 2021-04-26
AU2018350683A1 (en) 2020-04-02
CN111194319A (zh) 2020-05-22
UY37945A (es) 2019-05-31
CL2020001036A1 (es) 2020-10-23
US20200261461A1 (en) 2020-08-20
WO2019076817A1 (en) 2019-04-25
BR112020007679A2 (pt) 2020-10-20
KR20200073216A (ko) 2020-06-23

Similar Documents

Publication Publication Date Title
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
ECSP18001308A (es) Derivados de oxopiridina sustituidos
CL2017003404A1 (es) Compuestos antibacterianos
CU20150095A7 (es) Pirimidinas fusionadas sustituidas con trifluorometilo
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
CR20150479A (es) Composiciones antimicrobianas y métodos de uso relacionados
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
UY36196A (es) Compuestos para usar en el tratamiento antihelmíntico
MX2020004155A (es) Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
CR20150631A (es) Benzoxazoles sustituidos
CO2017005741A2 (es) Compuestos para tratar el cáncer
CL2015003780A1 (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.